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Introduction
Idiopathic pulmonary hemosiderosis (IPH) is a very
rare disease that causes diffuse alveolar hemorrhage.
Its clinical course is exceedingly variable, and delayed
diagnosis is common. Effective treatment of this dis-
ease requires a high degree of clinical suspicion and
accurate differential diagnosis. The clinical character-
istics of IPH include repeated episodes of hemoptysis,
diffuse pulmonary infiltration, and iron deficiency
anemia. Pathologic indication is abnormal hemosiderin
iron deposits in the alveoli macrophages. The estimated
incidence was 0.24 per million children in Sweden
and 1.23 per million in Japan.1 Most cases occur in chil-
dren and young adults, usually male.2 IPH is extremely
rare in adults. Only 10 cases have been reported in
the last 10 years. Here, we report a case of IPH in 
a middle-aged woman who responded favorably to
corticosteroid treatment.
Case Report
After 4 days of coughing fresh blood, a 50-year-old
Taiwanese postmenopausal housewife was examined
by the authors on February 18, 2005. She also com-
plained of productive cough, shortness of breath, and
orthopnea of 1 month’s duration. She had experienced
the same symptoms recurrently every 6 months for the
past 4 years. She denied nasal bleeding, hematuria,
body weight loss, or nocturnal sweating during the
course of her illness. Her past history was unremark-
able except that she had been receiving amlodipine
5mg/day for the treatment of hypertension for 4 years.
Physical examination revealed a middle-aged woman in
mild cardiopulmonary distress. Her conjunctivae were
pale. Wheezes and crackles could be heard from the
chest bilaterally. She did not have a murmur on heart
auscultation. Her liver and spleen were not palpable,
and she did not have pitting edema.
Peripheral white cell count was 13,430/mm3,
hemoglobin was 10.7 g/dL, and platelet count was
318,000/mm3. Serum biochemistry revealed blood
urea nitrogen of 14 mg/dL, creatinine of 0.7 mg/dL,
alanine aminotransferase of 27 IU/L, aspartate amino-
transferase of 27 IU/L, prothrombin time of 11.3
seconds, and activated partial thromboplastin time 
of 30.4 seconds. Serum C-reactive protein level was
0.5 mg/dL. Electrocardiography was normal. Chest
roentgenography showed diffuse alveolar infiltration
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in bilateral lower lungs (Figure 1A). Chest computed
tomography showed multiple patches of ground-glass
infiltrates in both lungs (Figure 1B). Repeated sputum
smear revealed no tuberculosis bacilli. Blood C3 and
C4 levels were within normal limits. Antinuclear anti-
body was negative (1:40×). The symptoms improved
spontaneously, and the patient was discharged 4 days
later.
On June 24, 2005, she was again hospitalized for
recurring hemoptysis. Chest radiography showed dif-
fuse alveolar infiltrates as noted previously. Peripheral
blood examination revealed microcytic hypochromic
anemia, with hemoglobin of 8.1 g/dL, mean corpus-
cular volume of 67.5 fL, mean corpuscular hemoglo-
bin of 19.5 pg, and mean corpuscular hemoglobin
concentration of 28.8 g/dL. Serum iron, total iron-
binding capacity, ferritin and transferrin levels were
not checked. Bronchoscopy disclosed normal bronchial
mucosa without active bleeding. Transbronchial biopsy
was performed. Pathologic findings were alveolar
hemorrhage and extravasation of red blood cells with
hemosiderin-laden macrophages in the alveolar spaces.
The iron-laden macrophages were confirmed by iron
stain using Perl’s technique (Figure 2). Blood anti-
glomerular basement membrane (anti-GBM) anti-
body and antineutrophil cytoplasmic antibody (ANCA)
were negative. IPH was diagnosed by excluding other
glomerular, cardiac and immunological disorders. As
in the previous clinical course, the symptoms and chest
roentgenographic lesions resolved spontaneously.
She suffered two further episodes of hemoptysis in
September and December 2005. A daily dose of 20 mg
prednisolone was started on December 8, 2005 and
tapered to 10 mg/day 1 month later. The patient cur-
rently remains on steroid therapy, and no further
episodes of hemoptysis have occurred.
Discussion
Diffuse alveolar hemorrhage represents a medical
emergency and requires an expedient method of
identification. The many causes of diffuse alveolar
hemorrhage include congenital anomaly, vasculitis,
immunologic diseases such as Goodpasture’s syndrome,
collagen vascular diseases and idiopathic conditions.2–6
In some patients, an intensive search for a specific etiol-
ogy ends up negative. Such cases are presently classified
as IPH.2
IPH is a disease of unknown etiology that normally
occurs in infancy or childhood. The disease is charac-
terized by the triad of hemoptysis, pulmonary infil-
trates on chest radiograph and iron deficiency anemia.
The course of the disease is variable, independent of age
and gender, and may involve spontaneous remission.
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Figure 1. (A) Chest radiography shows bilateral lower lobe consolidation. (B) Chest computed tomography shows multiple patches of
ground-glass infiltrates in both lung fields.
Figure 2. Lung tissue shows hemorrhage and aggregates of
hemosiderin-laden macrophages (hematoxylin & eosin, 400×).
Many Prussian blue ferric ferrocyanide particles can be seen in
the hemosiderin-laden macrophages (inset: iron stain, 400×).
The pulmonary hemorrhage may be clinically insignif-
icant or it may be massive with early death. Mean sur-
vival after diagnosis is 2.5–5 years.2,3 Anemia may be
the only presenting feature of IPH, which is due to
occult pulmonary hemorrhage.7 A report by Yao et al
described 5 cases of IPH treated over a 25-year
period.8 The classic IPH triad was noted at initial pres-
entation in only 2 of the 5 patients. The clinical course
of IPH was exceedingly variable; the mean delay
before diagnosis was 9 months. Maintaining a high
degree of clinical suspicion and including the disease
in the differential diagnoses are mandatory. The case
reported herein was not promptly diagnosed, probably
because IPH is extremely rare in adult patients.
Initial corticosteroid treatment may be effective in
some pediatric patients.7,9 Kiper et al reported 23
cases of pediatric IPH who were treated with corti-
costeroids administered in doses ranging from 5 mg
every other day to 2 mg/kg daily, depending on the
severity of the episodes.9 The duration of disease was
2–14 years. They concluded that their IPH patients
benefited from long-term steroid treatment, which in
turn resulted in a milder course. Long-term low-dose
steroid treatment apparently minimized medical crises
and assured prolonged survival.9 In most reported
cases, an immunosuppressive agent is included in main-
tenance therapy to prevent recurrence.8,10–12 Yao et al
reported recurrent bleeding episodes in 4 of 5 patients
given corticosteroids alone.8 All 5 patients required
immunosuppressive therapy to achieve symptom-free
status. Saeed et al speculated that long-term immuno-
suppressive therapy may improve the prognosis.12
Prolonged treatment with corticosteroids or immuno-
suppressive agents often produces significant side
effects. Tutor and Eid reported the successful treat-
ment of an IPH patient by using inhaled flunisolide.13
However, the time of inhaled steroid treatment and
follow-up were not long enough to allow a conclu-
sion to be drawn with regard to the effect of inhaled
steroid treatment on IPH.
Children and adolescents are likely to exhibit a rapid
disease course and poor prognosis. In adults, the course
is often prolonged, with less severe symptoms and a
more favorable prognosis.14 Most adult IPH patients
respond well to corticosteroids.15 Some authors recom-
mend a more effective therapy by using azathioprine
in combination with prednisolone.1,16 Hanip et al
reported a young female IPH patient who required
assisted ventilation. She failed to respond to corticos-
teroids and was oxygen-dependent until she succumbed
to the illness 2 years after initial presentation.17
The presence of serum ANCA may have prognostic
value. Blanco et al, in a retrospective 4-year study of
ANCA in 4 children with IPH, reported findings of
ANCA-positive sera in 3 of the 4 patients.18 In the same
study, he also noted that the patient with the highest
titer of ANCA had the worst prognosis. The case
reported herein had a negative ANCA. Active anti-
GBM disease may be absent of circulating anti-GBM
antibodies. Renal biopsy with immunofluorescent stud-
ies or follow-up blood anti-GBM antibody should be
considered in the diagnostic evaluation of subjects with
diffuse pulmonary hemorrhage, including those with
IPH.19 Regular follow-up of blood anti-GBM antibody
is recommended for cases similar to that reported here.
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